Ebola Sudan Protein

Ebola virus (EBOV) is a member of the Filoviridae family, which also includes the Marburg virus (MARV) and Sudan virus (SUDV). These viruses are known to cause severe viral hemorrhagic fevers in humans and non-human primates, with high mortality rates. The Sudan virus, in particular, has been responsible for several outbreaks in Africa, leading to significant morbidity and mortality .

Recombinant protein technology involves the use of genetic engineering to produce proteins in various host systems. This technology has been instrumental in the development of vaccines and therapeutics for various infectious diseases, including those caused by filoviruses. The recombinant proteins are typically produced by inserting the gene encoding the protein of interest into a suitable expression system, such as bacteria, yeast, insect cells, or mammalian cells .

The Ebola Sudan recombinant protein is a subunit vaccine candidate designed to elicit an immune response against the Sudan virus. This protein is typically the glycoprotein (GP) of the virus, which plays a crucial role in the virus’s ability to infect host cells. The GP is responsible for binding to host cell receptors and facilitating the fusion of the viral and host cell membranes .

The production of Ebola Sudan recombinant protein involves the use of expression systems such as the Drosophila S2 platform. This system allows for the production of highly purified recombinant subunit vaccines. The recombinant proteins are then formulated with adjuvants, such as CoVaccine HT™, to enhance the immune response .

Preclinical studies have shown that the Ebola Sudan recombinant protein elicits potent immune responses in various animal models, including mice, guinea pigs, and non-human primates. These studies have demonstrated high antigen-specific IgG titers and protection against lethal doses of the Sudan virus. The recombinant protein vaccines have shown no adverse reactions or clinical chemistry abnormalities in preclinical testing .